Drug Evaluation Committee Slide collection of explanations on how to introduce and utilize clinical trial methods that do not depend on visits to medical institutions
Clinical Evaluation Subcommittee
January 2022
The purpose of Task Force 3 of the Clinical Evaluation Committee 2021 is to increase interest and understanding of Decentralized Clinical Trial (DCT) among many people including pharmaceutical companies and medical institutions involved in clinical trials. The Clinical Evaluation Subcommittee has prepared a "Slide Book on the Introduction and Use of Decentralized Clinical Trial (DCT) Methods" to promote interest and understanding of DCT.
The Clinical Evaluation Subcommittee has published " Study on the Introduction and Utilization of Clinical Trial Methods that Do Not Depend on Visits toMedical Institutions " and " Study on the Utilization of Clinical Trial Methods that Do Not Depend on Visits to Medical Institutions - A Guide for Introduction in Japan" to promote efforts toward the implementation of DCT in Japan. -This slide presentation is based on the content of these reports .
This slide presentation can be used by selecting and choosing slides according to the user's purpose. We hope that the slides will be widely used in various presentations by pharmaceutical companies, medical institutions, service providers, and others, thereby helping to further promote the use of DCT in Japan. If you wish to modify the content of the slides, please make sure to clarify any quotations from previous reports or this slide presentation.
Related past deliverables
- Study on the introduction and utilization of clinical trial methods that do not depend on visits to medical institutions (September 2020)
- Study toward the introduction and utilization of clinical trial methods that do not depend on visits to medical institutions - a guide for introduction in Japan - (July 2021)
Deliverables of the Drug Evaluation Committee Return to list of all deliverables